Study of flu costs;Estudio de costes de la gripe

Atencion Primaria

Volumn 38, Issue 5, 2006, Pages 260-267

  Badia Llach, Xavier ^a,b   Roset Gamisans, Montserrat ^a   Francés Tudel, José M ^b   Álvarez Sanz, Concha ^c   Rubio Terrés, Carlos ^d  

^a Health Outcomes Research Europe   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c SA Barcelona   (Spain)

^d HERO Consulting   (Spain)

Author keywords

Costs; Influenza; Risk Factors

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT;

ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; EMERGENCY CARE; EPIDEMIC; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; PRIMARY MEDICAL CARE; RISK FACTOR; SPAIN;

EID: 33751014311     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092984     Document Type: Article

References (24)

1. Farreras P, Rozman C, editores. Medicina Interna. 14th ed. Madrid: Ediciones Harcourt; 2000. p. 2831.
2. Salleras I, Domínguez A. Impacto sanitario y económico de la vacunación antigripal inactivada. Vacunas. 2002;3:38-46.
3. Sullivan KM, Monto AS, Longini IM. Estimates of the US Health Impact of Influenza. Am J Public Health. 1993;83:1712-6.
4. Schwartz B, Bell DM, Hughes JM. Preventing the emergence of antimicrobial resistance: a call for action by clinicians, public health officials, and patients [editorial]. JAMA. 1997;278:944-5.
5. Turner D, Waitoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assessment. 2003;7:1-170.
6. Programa de actualización en vacunas: vacunación contra la gripe. Vacunas. 2003;módulo IIb:17-30.
7. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza. JAMA. 2000;283:1016-24.
8. Cañás M, Buschiazzo H. Gripe y medicamentos. Femeba Hoy. 2002;56:8-9.
9. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond). 1998;48:85-90.
10. Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Le Gales C, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med. 2002;162:1842-8.
11. Elaboración propia. Bases de datos de costes sanitarios Soikos'2000.
12. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo General de Especialidades Farmacéuticas. Madrid, 2000.
13. Encuesta de Salarios en la Industria y los Servicios. Base 1995. Tercer trimestre de 1999. Disponible en: http://www.ine.es
14. Precio según tarifa vigente 2000. Transportes Metropolitanos de Barcelona.
15. Precio según tarifa vigente 2000. Instituto Metropolitano del Taxi de Barcelona.
16. Riera P. Rentabilidad social de las infraestructuras: las rondas de Barcelona. Madrid: Civitas; 1993.
17. Fleming DM. Zanamivir in the treatment of influenza. Expert Opin Pharmacother. 2003;4:799-805.
18. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother. 1999;44 Suppl B:11-5.
19. Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail Older people. Arch Intern Med. 1998;158:645-50.
20. Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev Infect Dis. 1980;2:408-20.
21. Cox FM, Cobb MM, Chua WQ, McLaughlin TP, Okamoto LJ. Cost of treating influenza in emergency department and hospital settings. Am J Manag Care. 2000;6:205-14.
22. CDC Prevention and control of influenza. Recommendations of the Advisory Committee on Inmunnization Practices (ACIP). MMWR. 2002;51:1-32.
23. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278: 901-4.
24. Keystone Mercy Health Plan. Know antibiotics: don't use them if you don't need them. Keystone Mercy. 2001;5:2.